Study to assess aetiology, clinical and imaging characteristics of post Covid-19 pulmonary cavitation.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35360787.
- Also identified by DOI 10.4103/jfmpc.jfmpc_1425_21 and PMC identifier 8963656.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this study is to determine the aetiology and characteristics of pulmonary cavities that developed in patients recovering from COVID-19 infection. Between 1<sup>st</sup> May 2021 and 30<sup>st</sup> June 2021, we found 9 post COVID-19 patients who developed lung cavities on chest radiograph or CT during the follow-up period. These patients underwent routine blood examination, sputum examination and bronchoscopy to identify the aetiologies for the lung cavities. The duration from the onset of COVID-19 symptoms to the detection of lung cavities ranged from 18 to 82 days. Out of 7 patients, 4 had recovered from severe COVID-19 disease, 2 from moderate and 1 from mild disease. After the diagnostic workup, 5 patients were found to have COVID-19 associated pulmonary aspergillosis (CAPA), 1 patient with mucormycosis and 1 patient with mycobacterium infection. Two patients with CAPA also had bacterial infection; sputum culture from both these patients grew Klebsiella pneumonia. Lung cavities can develop in patients recovering from COVID-19 pneumonia and fungal infection is the most common cause for such cavities.